{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:53:07Z","timestamp":1788774787923,"version":"build-2803163510"},"reference-count":139,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.heliyon.2024.e34577","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T02:41:32Z","timestamp":1720924892000},"page":"e34577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Immune responses in COVID-19 patients: Insights into cytokine storms and adaptive immunity kinetics"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4335-715X","authenticated-orcid":false,"given":"Junguo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e34577_bib3","article-title":"World Health Organization: the COVID-19 pandemic is no longer considered a \"global health emergency","year":"2023","journal-title":"yet the COVID-19 virus continues to be lethal and mutate"},{"key":"10.1016\/j.heliyon.2024.e34577_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2021.104831","article-title":"Mutations in SARS-CoV-2; Consequences in structure, function, and pathogenicity of the virus","volume":"154","author":"Bakhshandeh","year":"2021","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.heliyon.2024.e34577_bib5","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.chempr.2020.04.023","article-title":"Chemistry and biology of SARS-CoV-2","volume":"6","author":"D\u00f6mling","year":"2020","journal-title":"Chem"},{"key":"10.1016\/j.heliyon.2024.e34577_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e34577_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41392-021-00845-4","article-title":"Escaping alveolar macrophage endosomal retention explains massive expansion of SARS-CoV-2 delta variant","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.heliyon.2024.e34577_bib8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/iub.2577","article-title":"Underlying selection for the diversity of spike protein sequences of SARS-CoV-2","volume":"74","author":"Ghosh","year":"2022","journal-title":"IUBMB Life"},{"key":"10.1016\/j.heliyon.2024.e34577_bib9","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.heliyon.2024.e34577_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41421-021-00258-1","article-title":"Distinct uptake, amplification, and release of SARS-CoV-2 by M1 and M2 alveolar macrophages","volume":"7","author":"Lv","year":"2021","journal-title":"Cell Discovery"},{"key":"10.1016\/j.heliyon.2024.e34577_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41423-021-00813-6","article-title":"SARS-CoV-2 treatment effects induced by ACE2-expressing microparticles are explained by the oxidized cholesterol-increased endosomal pH of alveolar macrophages","volume":"19","author":"Wang","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41392-022-01106-8","article-title":"Alveolar macrophages: achilles' heel of SARS-CoV-2 infection","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.heliyon.2024.e34577_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41422-021-00595-6","article-title":"Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2","volume":"32","author":"Gu","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.heliyon.2024.e34577_bib14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-022-01043-6","article-title":"Cell deaths: involvement in the pathogenesis and intervention therapy of COVID-19","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.heliyon.2024.e34577_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107225","article-title":"The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease","volume":"90","author":"Pasrija","year":"2021","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.heliyon.2024.e34577_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2023.07.019","article-title":"Epigenetic memory of coronavirus infection in innate immune cells and their progenitors","volume":"186","author":"Cheong","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e34577_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104851","article-title":"Probing long COVID through a proteomic lens: a comprehensive two-year longitudinal cohort study of hospitalised survivors","volume":"98","author":"Gu","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.heliyon.2024.e34577_bib18","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1016\/S2666-5247(22)00036-2","article-title":"SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study","volume":"3","author":"Guo","year":"2022","journal-title":"The Lancet. Microbe"},{"key":"10.1016\/j.heliyon.2024.e34577_bib19","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.immuni.2013.08.009","article-title":"Synergistic activation of inflammatory cytokine genes by interferon-\u03b3-induced chromatin remodeling and toll-like receptor signaling","volume":"39","author":"Qiao","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2024.e34577_bib20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.heliyon.2024.e34577_bib21","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.heliyon.2024.e34577_bib22","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.heliyon.2024.e34577_bib23","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2024.e34577_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102964","article-title":"Monocyte activation in systemic Covid-19 infection: assay and rationale","volume":"59","author":"Martinez","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.heliyon.2024.e34577_bib25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib26","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000034","article-title":"The NF-kappaB family of transcription factors and its regulation","volume":"1","author":"Oeckinghaus","year":"2009","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cytogfr.2020.06.001","article-title":"SARS-CoV-2 infection: the role of cytokines in COVID-19 disease","volume":"54","author":"Costela-Ruiz","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.heliyon.2024.e34577_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abm5505","article-title":"Innate immunological pathways in COVID-19 pathogenesis","volume":"7","author":"Paludan","year":"2022","journal-title":"Science Immunology"},{"key":"10.1016\/j.heliyon.2024.e34577_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.heliyon.2024.e34577_bib30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41590-020-00840-x","article-title":"Untuned antiviral immunity in COVID-19 revealed by temporal type I\/III interferon patterns and flu comparison","volume":"22","author":"Galani","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2022.11.020","article-title":"NFKB2 haploinsufficiency identified via screening for IFN-\u03b12 autoantibodies in children and adolescents hospitalized with SARS-CoV-2-related complications","volume":"151","author":"Bodansky","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2014.05.001","article-title":"HMGB1 in health and disease","volume":"40","author":"Kang","year":"2014","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.heliyon.2024.e34577_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.smim.2018.02.011","article-title":"High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells","volume":"38","author":"Andersson","year":"2018","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/imm.13623","article-title":"The role of HMGB1 in COVID-19-induced cytokine storm and its potential therapeutic targets: a review","volume":"169","author":"Wulandari","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.heliyon.2024.e34577_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121393","article-title":"DAMPs\/PAMPs induce monocytic TLR activation and tolerance in COVID-19 patients; nucleic acid binding scavengers can counteract such TLR agonists","volume":"283","author":"Naqvi","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.heliyon.2024.e34577_bib36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41435-021-00140-w","article-title":"Role of DAMPs in respiratory virus-induced acute respiratory distress syndrome-with a preliminary reference to SARS-CoV-2 pneumonia","volume":"22","author":"Land","year":"2021","journal-title":"Gene Immun."},{"issue":"21 Suppl 1","key":"10.1016\/j.heliyon.2024.e34577_bib37","article-title":"High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule","author":"Yang","year":"2015","journal-title":"Mol. Med. (Camb.)"},{"key":"10.1016\/j.heliyon.2024.e34577_bib38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s10020-020-00172-4","article-title":"Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?","volume":"26","author":"Andersson","year":"2020","journal-title":"Mol. Med. (Camb.)"},{"key":"10.1016\/j.heliyon.2024.e34577_bib39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib40","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.3389\/fimmu.2020.01580","article-title":"Severe COVID-19: NLRP3 inflammasome dysregulated","volume":"11","author":"van den Berg","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41420-021-00428-w","article-title":"SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes","volume":"7","author":"Ferreira","year":"2021","journal-title":"Cell Death Discovery"},{"key":"10.1016\/j.heliyon.2024.e34577_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108887","article-title":"Gasdermin D mediates the maturation and release of IL-1\u03b1 downstream of inflammasomes","volume":"34","author":"Tsuchiya","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.heliyon.2024.e34577_bib43","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/infdis\/jiab005","article-title":"Early differences in cytokine production by severity of coronavirus disease 2019","volume":"223","author":"Tjan","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e34577_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155302","article-title":"Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19","volume":"137","author":"Sat\u0131\u015f","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.heliyon.2024.e34577_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105132","article-title":"Targeting IL-6 trans-signalling by sgp130Fc attenuates severity in SARS-CoV-2 -infected mice and reduces endotheliopathy","volume":"103","author":"Rodr\u00edguez-Hern\u00e1ndez","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.heliyon.2024.e34577_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.891456","article-title":"Identification of IL-6 signalling components as predictors of severity and outcome in COVID-19","volume":"13","author":"Rodr\u00edguez-Hern\u00e1ndez","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib47","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw2262","article-title":"TH17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identity","volume":"5","author":"Harbour","year":"2020","journal-title":"Science Immunology"},{"key":"10.1016\/j.heliyon.2024.e34577_bib49","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41577-020-0323-4","article-title":"COVID-19 vaccine design: the Janus face of immune enhancement","volume":"20","author":"Hotez","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib50","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/08830185.2021.1883600","article-title":"COVID-19: immunology, immunopathogenesis and potential therapies","volume":"41","author":"Bhardwaj","year":"2022","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-04142-6","article-title":"Untimely TGF\u03b2 responses in COVID-19 limit antiviral functions of NK cells","volume":"600","author":"Witkowski","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34577_bib53","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1128\/JVI.05738-11","article-title":"Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion","volume":"86","author":"Jensen","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00074-20","article-title":"Immunopathogenesis of coronavirus-induced acute respiratory distress syndrome (ARDS): potential infection-associated hemophagocytic lymphohistiocytosis","volume":"34","author":"Quan","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.heliyon.2024.e34577_bib55","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","volume":"20","author":"Merad","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib56","article-title":"Chloroquine and hydroxychloroquine in covid-19","volume":"369","author":"Ferner","year":"2020","journal-title":"Br. Med. J. Int. Ed."},{"key":"10.1016\/j.heliyon.2024.e34577_bib57","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"The Lancet. Rheumatology"},{"key":"10.1016\/j.heliyon.2024.e34577_bib58","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with covid-19","volume":"384","author":"Gordon","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e34577_bib59","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1126\/science.abc7424","article-title":"Broad neutralization of SARS-related viruses by human monoclonal antibodies","volume":"369","author":"Wec","year":"2020","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.heliyon.2024.e34577_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e34577_bib61","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M20-3012","article-title":"Prevalence of asymptomatic SARS-CoV-2 infection : a narrative review","volume":"173","author":"Oran","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.heliyon.2024.e34577_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e34577_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e34577_bib64","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34577_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e34577_bib66","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.abd3871","article-title":"Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans","volume":"370","author":"Mateus","year":"2020","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.heliyon.2024.e34577_bib67","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","article-title":"SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19","volume":"587","author":"Braun","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34577_bib68","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib69","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: a decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2024.e34577_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.10.001","article-title":"Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19","volume":"183","author":"Meckiff","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e34577_bib71","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00566-21","article-title":"Mechanisms of antiviral cytotoxic CD4 T cell differentiation","volume":"95","author":"Knudson","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib72","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd2071","article-title":"Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome","volume":"5","author":"Weiskopf","year":"2020","journal-title":"Science Immunology"},{"key":"10.1016\/j.heliyon.2024.e34577_bib73","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.immuni.2019.11.007","article-title":"Back to the future: effector fate during T cell exhaustion","volume":"51","author":"Buchholz","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2024.e34577_bib74","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34577_bib75","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41591-020-01143-2","article-title":"Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells","volume":"27","author":"Schulien","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2024.e34577_bib76","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41590-023-01608-9","article-title":"Multimodal single-cell datasets characterize antigen-specific CD8+ T cells across SARS-CoV-2 vaccination and infection","volume":"24","author":"Zhang","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib77","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41590-022-01184-4","article-title":"SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells","volume":"23","author":"Minervina","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib78","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41586-021-04280-x","article-title":"Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection","volume":"602","author":"Adamo","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34577_bib79","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abe4782","article-title":"Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8+ T cells","volume":"6","author":"Kusnadi","year":"2021","journal-title":"Science Immunology"},{"key":"10.1016\/j.heliyon.2024.e34577_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2021.04.006","article-title":"CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses","volume":"54","author":"Lineburg","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2024.e34577_bib81","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2024.e34577_bib82","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients","volume":"5","author":"Premkumar","year":"2020","journal-title":"Science Immunology"},{"key":"10.1016\/j.heliyon.2024.e34577_bib83","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.heliyon.2024.e34577_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e34577_bib85","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34577_bib86","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34577_bib87","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.heliyon.2024.e34577_bib88","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e34577_bib89","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/joim.13372","article-title":"Immunity to SARS-CoV-2 induced by infection or vaccination","volume":"291","author":"Castro Dopico","year":"2022","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.heliyon.2024.e34577_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2024.e34577_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.10.040","article-title":"Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19","volume":"147","author":"Cervia","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib92","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4250","article-title":"Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity","volume":"370","author":"Shrock","year":"2020","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.heliyon.2024.e34577_bib93","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41590-020-00826-9","article-title":"Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum","volume":"22","author":"Weisberg","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib94","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216345","article-title":"Acquired immunity against SARS-CoV-2 infection and vaccination","volume":"15","author":"Renia","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.heliyon.2024.e34577_bib95","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.7150\/ijbs.59233","article-title":"mRNA vaccines for COVID-19: what, why and how","volume":"17","author":"Park","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.heliyon.2024.e34577_bib96","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34577_bib97","doi-asserted-by":"crossref","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.heliyon.2024.e34577_bib98","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-021-03841-4","article-title":"Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine","volume":"597","author":"Oberhardt","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34577_bib99","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34577_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2020.11.009","article-title":"SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation","volume":"53","author":"Lederer","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2024.e34577_bib101","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody persistence through 6 Months after the second dose of mRNA-1273 vaccine for covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e34577_bib102","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e34577_bib103","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib104","article-title":"SARS-CoV-2 variants, vaccines, and host immunity","volume":"12","author":"Mistry","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib105","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1158\/0008-5472.CAN-21-3554","article-title":"Longitudinal SARS-CoV-2 mRNA vaccine-induced humoral immune responses in patients with cancer","volume":"81","author":"Figueiredo","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e34577_bib106","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood.2021012251","article-title":"COVID-19 in patients with hematologic malignancy","volume":"140","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e34577_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.832924","article-title":"Local and systemic immunity are impaired in end-stage-renal-disease patients treated with hemodialysis, peritoneal dialysis and kidney transplant recipients immunized with BNT162b2 pfizer-BioNTech SARS-CoV-2 vaccine","volume":"13","author":"Piotrowska","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/ph16040574","article-title":"Maintenance of potent cellular and humoral immune responses in long-term hemodialysis patients after 1273-mRNA SARS-CoV-2 vaccination","volume":"16","author":"Gonzalez-Perez","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.heliyon.2024.e34577_bib109","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.23405","article-title":"Assessment of adverse reactions, antibody patterns, and 12-month outcomes in the mother-infant dyad after COVID-19 mRNA vaccination in pregnancy","volume":"6","author":"Cassidy","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.heliyon.2024.e34577_bib110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13073-022-01043-9","article-title":"Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study","volume":"14","author":"Selma-Royo","year":"2022","journal-title":"Genome Med."},{"key":"10.1016\/j.heliyon.2024.e34577_bib111","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s15010-023-02111-x","article-title":"IgG antibody levels against the SARS-CoV-2 spike protein in mother-child dyads after COVID-19 vaccination","volume":"52","author":"Mu\u00f1oz-G\u00f3mez","year":"2024","journal-title":"Infection"},{"key":"10.1016\/j.heliyon.2024.e34577_bib112","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1093\/cid\/ciac480","article-title":"Kinetics of maternally derived anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in infants in relation to the timing of antenatal vaccination","volume":"76","author":"Rottenstreich","year":"2023","journal-title":"Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.heliyon.2024.e34577_bib113","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cmi.2021.10.003","article-title":"Timing of SARS-CoV-2 vaccination during the third trimester of pregnancy and transplacental antibody transfer: a prospective cohort study","volume":"28","author":"Rottenstreich","year":"2022","journal-title":"Clin. Microbiol. Infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"key":"10.1016\/j.heliyon.2024.e34577_bib114","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/jamapediatrics.2021.5683","article-title":"Maternal and neonatal SARS-CoV-2 immunoglobulin G antibody levels at delivery after receipt of the BNT162b2 messenger RNA COVID-19 vaccine during the second trimester of pregnancy","volume":"176","author":"Kugelman","year":"2022","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.heliyon.2024.e34577_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.777103","article-title":"COVID-19 mRNA vaccination in lactation: assessment of adverse events and vaccine related antibodies in mother-infant dyads","volume":"12","author":"Golan","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib116","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1473-3099(23)00278-5","article-title":"Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant","volume":"23","author":"Yamasoba","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e34577_bib117","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1473-3099(23)00070-1","article-title":"Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate","volume":"23","author":"Uraki","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e34577_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109968","article-title":"Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2","volume":"117","author":"Firouzabadi","year":"2023","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.heliyon.2024.e34577_bib119","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065944","article-title":"mRNA vaccines against SARS-CoV-2: advantages and caveats","volume":"24","author":"Echaide","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e34577_bib120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41541-023-00654-6","article-title":"Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities-workshop report","volume":"8","author":"Knisely","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34577_bib121","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41565-023-01404-4","article-title":"Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines","volume":"18","author":"Han","year":"2023","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2023.04.024","article-title":"ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines","volume":"186","author":"Hoffmann","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e34577_bib123","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","volume":"591","author":"Gaebler","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34577_bib124","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41392-021-00777-z","article-title":"SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection","volume":"6","author":"Zhan","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.heliyon.2024.e34577_bib125","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1093\/cid\/ciab999","article-title":"Duration of severe acute respiratory syndrome coronavirus 2 natural immunity and protection against the delta variant: a retrospective cohort study","volume":"75","author":"Kim","year":"2022","journal-title":"Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.heliyon.2024.e34577_bib126","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.777858","article-title":"SARS-CoV-2 specific IgG antibodies persist over a 12-month period in oral mucosal fluid collected from previously infected individuals","volume":"12","author":"Chellamuthu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108814","article-title":"Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection","volume":"230","author":"Dehgani-Mobaraki","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib128","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.793953","article-title":"Sequential analysis of binding and neutralizing antibody in COVID-19 convalescent patients at 14 Months after SARS-CoV-2 infection","volume":"12","author":"Rosati","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib129","article-title":"Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19: a longitudinal cohort study","author":"Guo","year":"2023","journal-title":"The Lancet. Microbe"},{"key":"10.1016\/j.heliyon.2024.e34577_bib130","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1473-3099(22)00801-5","article-title":"Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression","volume":"23","author":"Bobrovitz","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e34577_bib131","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(23)01424-1","article-title":"Extra data to confirm waning protection of omicron (B.1.1.529) natural immunity","volume":"402","author":"Flacco","year":"2023","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.heliyon.2024.e34577_bib132","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","article-title":"BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection","volume":"608","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34577_bib133","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","article-title":"Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5","volume":"608","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34577_bib134","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-022-04856-1","article-title":"Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2","volume":"607","author":"Uraki","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34577_bib135","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34577_bib136","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34577_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.09.003","article-title":"The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages","volume":"184","author":"Martin","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e34577_bib138","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.heliyon.2024.e34577_bib139","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-022-05644-7","article-title":"Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution","volume":"614","author":"Cao","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34577_bib140","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1473-3099(23)00060-9","article-title":"Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study","volume":"23","author":"Tan","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e34577_bib141","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0140-6736(22)02465-5","article-title":"Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis","volume":"401","author":"Team","year":"2023","journal-title":"Lancet (London, England)"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024106081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024106081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:00:45Z","timestamp":1773842445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024106081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":139,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2405844024106081"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34577","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune responses in COVID-19 patients: Insights into cytokine storms and adaptive immunity kinetics","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e34577"}}